SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Abstract

November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.

Cited by papers we hold 27

• TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry · 2023
  No notice
• Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants · 2023
  No notice
• Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant · 2023
  No notice
• COVID-19 outbreak: Impact on global economy · 2023
  No notice
• Circular RNA vaccine in disease prevention and treatment · 2023
  No notice
• Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab · 2022
  Not checked
• Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes · 2022
  No notice
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation · 2022
  Not checked
• Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission · 2022
  No notice
• Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study · 2022
  No notice
• Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains · 2022
  No notice
• Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1 · 2022
  No notice
• Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 · 2022
  No notice
• Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct · 2022
  No notice
• BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection · 2022
  No notice
• SARS-CoV-2 Omicron variant: recent progress and future perspectives · 2022
  No notice
• Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance · 2022
  No notice
• COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice

and 7 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.